Oncolytics Biotech® Inc. (Nasdaq: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for ...

Oncolytics Biotech® Inc. (Nasdaq: ONCY) (TSX: ONC) ("Oncolytics" or the "Company"), a leading clinical-stage company ...

Integrated biomarker analyses confirm viral replication, interferon signaling, and a surge in tumor-infiltrating lymphocytes ...

A new study that analyzed the tumor microenvironment of pancreatic cancer revealed the cause of tumor cell resistance to immunotherapy and resulted in new treatment strategies.

Our immune systems have the potential to find and destroy cancer cells. But cancer cells can be clever and develop tricks to evade the immune system. Cold Spring Harbor Laboratory Professor&nbsp ...

Pushing past pancreatic tumors’ defenses Date: February 16, 2022 Source: Cold Spring Harbor Laboratory Summary: Researchers found that some cancer cells weave a deactivating signal into a ...

Pancreatic ductal adenocarcinoma (PDAC) is the most common form of pancreatic cancer. The disease is almost always fatal, with a 10-year survival rate of around 1 percent. The prognosis is ...

Pancreatic cancer, which was predicted to become the second leading cause of cancer death as early as 2015, eludes treatment for several reasons, not the least of which is tumor heterogeneity.

So-called "hot" tumors filled with T cells are often considered to be more sensitive to immunotherapy compared to "cold" tumors with fewer T cells, but a clear demonstration of why has eluded ...

So-called "hot" tumors filled with T cells are often considered to be more sensitive to immunotherapy compared to "cold" tumors with fewer T cells, but a clear demonstration of why has eluded ...